Trident Texofab [TTFL] vs Raymond [RAYMOND] Detailed Stock Comparison
Trident Texofab
BSE
Loading...
Raymond
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Trident Texofab wins in 4 metrics, Raymond wins in 15 metrics, with 0 ties. Raymond appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Trident Texofab | Raymond | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 158.94 | 90.93 | Raymond |
| Price-to-Book Ratio | 7.32 | 1.05 | Raymond |
| Debt-to-Equity Ratio | 62.67 | 17.81 | Raymond |
| PEG Ratio | 36.56 | -3.28 | Raymond |
| EV/EBITDA | 83.32 | 24.43 | Raymond |
| Profit Margin (TTM) | 2.28% | 271.84% | Raymond |
| Operating Margin (TTM) | 5.90% | 3.39% | Trident Texofab |
| EBITDA Margin (TTM) | 5.90% | 3.39% | Trident Texofab |
| Return on Equity | 5.31% | 183.56% | Raymond |
| Return on Assets (TTM) | 2.50% | 98.90% | Raymond |
| Free Cash Flow (TTM) | $-137.22M | $752.80M | Raymond |
| 1-Year Return | 606.97% | -63.75% | Trident Texofab |
| Price-to-Sales Ratio (TTM) | 4.08 | 1.90 | Raymond |
| Enterprise Value | $5.04B | $43.35B | Raymond |
| EV/Revenue Ratio | 4.05 | 2.11 | Raymond |
| Gross Profit Margin (TTM) | 15.72% | 40.59% | Raymond |
| Revenue per Share (TTM) | $108 | $309 | Raymond |
| Earnings per Share (Diluted) | $2.13 | $6.47 | Raymond |
| Beta (Stock Volatility) | -1.25 | -0.09 | Trident Texofab |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Trident Texofab vs Raymond Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Trident Texofab | 1.91% | 8.03% | 33.90% | 59.72% | 104.69% | 101.11% |
| Raymond | -1.20% | 1.04% | -4.34% | -17.32% | -59.55% | -65.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Trident Texofab | 606.97% | 201.18% | 1,145.49% | 698.61% | 698.61% | 698.61% |
| Raymond | -63.75% | -49.70% | 111.48% | 27.38% | 45.95% | 42.36% |
News Based Sentiment: Trident Texofab vs Raymond
Trident Texofab
News based Sentiment: POSITIVE
September was a month of consistently positive developments for Trident Texofab, marked by strong stock performance, positive financial results, and overwhelmingly bullish investor sentiment. The company's continued outperformance and operational efficiency suggest a strong investment case, despite high valuation metrics.
Raymond
News based Sentiment: MIXED
October brought a mix of positive and negative developments for Raymond Ltd., including a regulatory filing, a potential sell signal, analyst recommendations, and fluctuating share prices. The conflicting signals create a balanced, though uncertain, investment picture.
Performance & Financial Health Analysis: Trident Texofab vs Raymond
| Metric | TTFL | RAYMOND |
|---|---|---|
| Market Information | ||
| Market Cap | ₹5.08B | ₹41.42B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 24,786 | 259,769 |
| 90 Day Avg. Volume | 20,038 | 237,999 |
| Last Close | ₹345.00 | ₹581.25 |
| 52 Week Range | ₹146.25 - ₹345.00 | ₹523.10 - ₹1,908.00 |
| % from 52W High | 0.00% | -69.54% |
| All-Time High | ₹345.00 (Oct 06, 2025) | ₹3,496.00 (Jul 08, 2024) |
| % from All-Time High | 0.00% | -83.37% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | -0.44% |
| Quarterly Earnings Growth | 0.46% | -0.28% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 2.72% |
| Operating Margin (TTM) | 0.06% | 0.03% |
| Return on Equity (TTM) | 0.05% | 1.84% |
| Debt to Equity (MRQ) | 62.67 | 17.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹46.27 | ₹558.44 |
| Cash per Share (MRQ) | ₹2.24 | ₹114.41 |
| Operating Cash Flow (TTM) | ₹-106,030,000 | ₹69.27B |
| Levered Free Cash Flow (TTM) | ₹25.10M | ₹76.31B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Trident Texofab vs Raymond
| Metric | TTFL | RAYMOND |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 158.94 | 90.93 |
| Forward P/E | N/A | 4.53 |
| PEG Ratio | 36.56 | -3.28 |
| Price to Sales (TTM) | 4.08 | 1.90 |
| Price to Book (MRQ) | 7.32 | 1.05 |
| Market Capitalization | ||
| Market Capitalization | ₹5.08B | ₹41.42B |
| Enterprise Value | ₹5.04B | ₹43.35B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.05 | 2.11 |
| Enterprise to EBITDA | 83.32 | 24.43 |
| Risk & Other Metrics | ||
| Beta | -1.25 | -0.09 |
| Book Value per Share (MRQ) | ₹46.27 | ₹558.44 |
Financial Statements Comparison: Trident Texofab vs Raymond
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TTFL | RAYMOND |
|---|---|---|
| Revenue/Sales | ₹280.77M | ₹5.24B |
| Cost of Goods Sold | ₹236.63M | ₹3.11B |
| Gross Profit | ₹44.14M | ₹2.13B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹16.56M | ₹177.70M |
| EBITDA | ₹25.03M | ₹852.70M |
| Pre-Tax Income | ₹13.69M | ₹282.10M |
| Income Tax | ₹3.53M | ₹75.90M |
| Net Income (Profit) | ₹10.16M | ₹53.28B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TTFL | RAYMOND |
|---|---|---|
| Cash & Equivalents | ₹1.09M | ₹343.70M |
| Total Current Assets | ₹737.44M | ₹52.03B |
| Total Current Liabilities | ₹407.50M | ₹30.16B |
| Long-Term Debt | ₹102.71M | ₹3.45B |
| Total Shareholders Equity | ₹472.39M | ₹41.58B |
| Retained Earnings | ₹77.13M | ₹18.59B |
| Property, Plant & Equipment | ₹31.11M | ₹8.90B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TTFL | RAYMOND |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TTFL | RAYMOND |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 24,786 | 259,769 |
| Average Daily Volume (90 Day) | 20,038 | 237,999 |
| Shares Outstanding | 13.56M | 66.55M |
| Float Shares | 7.61M | 30.03M |
| % Held by Insiders | 0.38% | 0.52% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Trident Texofab vs Raymond
| Metric | TTFL | RAYMOND |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹5.33 |
| 3-Year Avg Dividend Yield | N/A | 0.31% |
| 3-Year Total Dividends | ₹0.00 | ₹16.00 |
| Ex-Dividend Date | N/A | Jun 13, 2024 |